Compare DexCom, Inc. (DXCM) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Zeta Global Holdings Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: DexCom, Inc. is far larger — about 3.8× Zeta Global Holdings Corp's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Zeta Global Holdings Corp for 19 Days on average.
| DXCM | ZETA | |
|---|---|---|
Market Cap | $31.86B | $8.29B |
Volume | 3,607,070 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $92.34 | $33.74 |
52-Week Low | $54.84 | $14.55 |
Typical Hold Time | 62 Days | 19 Days |
Enterprise Value | $31.32B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
ZETA trades at $33.03, down 2.1% today but remains near recent highs with strong technical momentum. The company shows robust revenue growth with $1.3B in 2025 and projected $1.6B in 2026, though profitability remains challenged with negative net margins. Recent earnings beats and expanding customer base (197 superscale customers in Q2 2026) support the bullish analyst consensus.
ZETA presents a growth story with expanding AI platform adoption and international expansion, but faces execution risks amid negative cash flow and high valuation multiples. The stock's 75% buy rating from analysts suggests upside potential, though investors should monitor margin improvement and cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
